Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06071013 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 23, 2025 (before its estimated August 27, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Start date changed from estimate of Sep 28, 2023 to Feb 23, 2024
    • Study sites: 0 to 1
    • Interventions: Nintedanib, gefitinib, erlotinib, afatinib (Drug) to Nintedanib, gefitinib, erlotinib, afatinib, osimertinib (Drug)
    • Eligibility criteria shortened, about 8 words
    • Study description expanded, about 1 word
    • Collaborators expanded, about 4 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
Trial Details
NCT Number NCT06071013
Lead Sponsor China Medical University Hospital
Collaborators: China Medical University, Taiwan
Conditions
(from sponsor)		 Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov